The novel PDLIM2 nanomedicine enhances chemoimmunotherapy for complete cure of lung cancer.

Lineage resolved single-cell RNA-seq of mammary carcinoma models uncovers a metabolic vulnerability of taxane-resistant clones.

Oncoprotein BCL6 confers tumor adaptive resistance to genotoxic stress through the IFN-BCL6-PTEN axis in solid tumors and presents a promising combinational target for chemo-sensitization.

Dalpiciclib could partially abrogate ER nuclear transportation induced by pyrotinib in HER2+HR+ breast cancer and CALML5 could serve as a potential risk factor in the treatment of HER2+HR+ breast cancer.

Overlaying single cell readouts of cell cycle and apoptosis onto a multidimensional analysis of pulsed cisplatin signalling dynamics reveals targetable mechanisms of platinum resistance in lung adenocarcinoma.

Elucidation of GLI1-Notch1 axis as key determinant of racial disparity in TNBC growth in African American and White American women.

Genetic analysis and biochemical approaches reveal that chemorefractory properties are reversed by inhibiting mucin secretion, thus providing a means to curb the growth and spread of colorectal cancer.

Proteomic and metabolomic analyses reveal how mannose exerts its anticancer activity.

Stereotactic body radiotherapy combined with immunotherapy and chemotherapy in neoadjuvant setting exhibited a promising anti-tumor activity and an acceptable safety profile in triple-negative breast cancer patients.

Inhibiting the RiBi pathway impedes both EMT and MET processes, enhancing chemotherapy efficacy and presenting a novel avenue to tackle advanced breast cancer treatment resistance.